Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paradigm BiopharmaceuticalsASX:PAR -2.78%24 3-Year EBITDA Growth Rate is 28.70% as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 1,131 Biotechnology companies, Paradigm Biopharmaceuticals ranks better than 65.25% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 28.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -2.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Paradigm Biopharmaceuticals was 28.70% per year. The lowest was -45.60% per year. And the median was -11.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Paradigm Biopharmaceuticals 3-Year EBITDA Growth Rate Related Terms
ASX:PAR vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Paradigm Biopharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paradigm Biopharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Paradigm Biopharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 28.70% mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a 3-Year EBITDA Growth Rate of 28.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Paradigm Biopharmaceuticals and its competitors. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #393 out of 1131 companies in the Biotechnology industry, placing it in the top 34.7%.
Is Paradigm Biopharmaceuticals' 3-Year EBITDA Growth Rate too high?
Paradigm Biopharmaceuticals' current 3-Year EBITDA Growth Rate is 28.70%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Paradigm Biopharmaceuticals' value of 28.70% is 92.6% above this industry median. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #393 out of 1131 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #393 out of 1131 companies for 3-Year EBITDA Growth Rate. This puts Paradigm Biopharmaceuticals in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Paradigm Biopharmaceuticals' value of 28.70% is 92.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paradigm Biopharmaceuticals's current 3-Year EBITDA Growth Rate of 28.70% is 92.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Paradigm Biopharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paradigm Biopharmaceuticals's current 3-Year EBITDA Growth Rate is 28.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current 3-Year EBITDA Growth Rate of 28.70%. The current 3-Year EBITDA Growth Rate is 28.70% and 92.6% above the Biotechnology industry median of 14.90. Paradigm Biopharmaceuticals' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current 3-Year EBITDA Growth Rate is 28.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
24GF Score
Get the complete analysis for ASX:PAR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PAR has been successfully added to your 
